Innovent Biologics and Roche are collaborating to accelerate the development of IBI3009, a potential treatment for advanced small cell lung cancer. Roche gains exclusive rights for global development, manufacturing, and commercialization with milestones up to $1bn for Innovent.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing